The company will start a phase 2/3 trial of PF-08634404 in March.
ApexOnco Front Page
Recent articles
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
First-in-human study starts include radioligands from Akiram and Philogen.
